Comparative Study
doi: 10.1016/0732-8893(89)90115-6.
Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin
Affiliations
- PMID: 2515025
- DOI: 10.1016/0732-8893(89)90115-6
Item in Clipboard
Comparative Study
Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin
Diagn Microbiol Infect Dis.
1989 Sep-Oct.
Abstract
Lomefloxacin was found to be comparable to ciprofloxacin in its ability to inhibit the in vitro growth of Mycoplasma pneumoniae (MIC range 2-8 mcg/ml), but it was significantly less active than erythromycin. Although 30 different strains from widely differing geographic areas and isolation time periods were examined, no macrolide-resistant strains were observed.
Similar articles
-
Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.Eur J Clin Microbiol Infect Dis. 1990 Nov;9(11):838-41. doi: 10.1007/BF01967388. Eur J Clin Microbiol Infect Dis. 1990. PMID: 1964899
-
Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin.Antimicrob Agents Chemother. 1991 Mar;35(3):587-9. doi: 10.1128/AAC.35.3.587. Antimicrob Agents Chemother. 1991. PMID: 1903913 Free PMC article.
-
In-vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to clinafloxacin, PD 131628, ciprofloxacin and comparator drugs.J Antimicrob Chemother. 1997 Aug;40(2):308-9. doi: 10.1093/jac/40.2.308. J Antimicrob Chemother. 1997. PMID: 9302005 No abstract available.
-
In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to sparfloxacin and PD 127391.Antimicrob Agents Chemother. 1991 Jun;35(6):1181-5. doi: 10.1128/AAC.35.6.1181. Antimicrob Agents Chemother. 1991. PMID: 1929260 Free PMC article.
-
In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae.J Antimicrob Chemother. 1994 Dec;34(6):875-83. doi: 10.1093/jac/34.6.875. J Antimicrob Chemother. 1994. PMID: 7730231
Cited by
-
In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae.Antimicrob Agents Chemother. 2001 Jun;45(6):1908-10. doi: 10.1128/AAC.45.6.1908-1910.2001. Antimicrob Agents Chemother. 2001. PMID: 11353651 Free PMC article.
-
In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.Antimicrob Agents Chemother. 1993 Sep;37(9):1826-30. doi: 10.1128/AAC.37.9.1826. Antimicrob Agents Chemother. 1993. PMID: 8239590 Free PMC article.
-
Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae.Antimicrob Agents Chemother. 1995 Dec;39(12):2770-3. doi: 10.1128/AAC.39.12.2770. Antimicrob Agents Chemother. 1995. PMID: 8593017 Free PMC article.
-
Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.Eur J Clin Microbiol Infect Dis. 1990 Nov;9(11):838-41. doi: 10.1007/BF01967388. Eur J Clin Microbiol Infect Dis. 1990. PMID: 1964899
-
Quinolones in the treatment of lower respiratory tract infections caused by intracellular pathogens.Infection. 1991;19 Suppl 7:S365-71. doi: 10.1007/BF01715829. Infection. 1991. PMID: 1804785 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
